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Abstract
Background: Older adults who live in rural areas experience significant disparities in health status and access to mental health
care. "Telepsychology," (also referred to as "telepsychiatry," or "telemental health") represents a potential strategy towards
addressing this longstanding problem. Older adults may benefit from telepsychology due to its: (1) utility to address existing
problematic access to care for rural residents; (2) capacity to reduce stigma associated with traditional mental health care; and
(3) utility to overcome significant age-related problems in ambulation and transportation. Moreover, preliminary evidence
indicates that telepsychiatry programs are often less expensive for patients, and reduce travel time, travel costs, and time off
from work. Thus, telepsychology may provide a cost-efficient solution to access-to-care problems in rural areas.
Methods: We describe an ongoing four-year prospective, randomized clinical trial comparing the effectiveness of an empirically
supported treatment for major depressive disorder, Behavioral Activation, delivered either via in-home videoconferencing
technology ("Telepsychology") or traditional face-to-face services ("Same-Room"). Our hypothesis is that in-
homeTelepsychology service delivery will be equally effective as the traditional mode (Same-Room). Two-hundred twenty-four
(224) male and female elderly participants will be administered protocol-driven individual Behavioral Activation therapy for
depression over an 8-week period; and subjects will be followed for 12-months to ascertain longer-term effects of the treatment
on three outcomes domains: (1) clinical outcomes (symptom severity, social functioning); (2) process variables (patient
satisfaction, treatment credibility, attendance, adherence, dropout); and (3) economic outcomes (cost and resource use).
Discussion: Results from the proposed study will provide important insight into whether telepsychology service delivery is as
effective as the traditional mode of service delivery, defined in terms of clinical, process, and economic outcomes, for elderly
patients with depression residing in rural areas without adequate access to mental health services.
Trial registration: National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier# NCT00324701).
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Background
People who live in rural areas experience significant dis-
parities in health status and access to care compared to
their urban counterparts [1,2]. Access to appropriate men-
tal health care services represents a significant problem in
many rural and remote areas and as the ageing population
expands, this problem will intensify over the next several
decades without innovative solutions [1-4]. There is grow-
ing awareness that specifically tailored treatment and serv-
ice delivery strategies are frequently needed for different
populations of adult consumers of mental health services
[3,5]. Access to appropriate mental health care services
represents a significant problem in many rural and remote
areas and this problem will intensify over the next several
decades without innovative solutions [4]. In the mental
health field, "telepsychology," (or "telepsychiatry" or
"telemental health") represents a strategy for potentially
addressing this longstanding access to care problem [6-8].
The strengths of telemental health include well-docu-
mented patient and provider satisfaction for a range of
services [9-15]; strong support for the reliability of clinical
assessments (eg, neuropsychological testing, clinical inter-
views, and mental status exams) relative to face-to-face
assessments [16-20]; and evidence that medical patients
would choose to receive it if it was available and would
improve their access to care [21]. In addition, research has
documented the effectiveness of telepsychiatry to treat
specific mental health diagnoses such as depression [22-
24] and anxiety disorders [25-27], as well as its effective-
ness with specific populations including incarcerated
patients [28,29], children and adolescents [30], rural pop-
ulations [13,31,32] and older adults [16,33-35]. The
weaknesses identified in the research literature include a
paucity of rigorous cost and efficacy studies, particularly
for specific populations, and lack of research into the
legal, ethical and regulatory issues inherent in this appli-
cation of technology to clinical practice [6,7,36].
The use of telemedicine to address urgent patient care
needs for older adults has been identified as the first two
of five priority areas for future development by the
Department of Veterans Affairs (VA) [37]. Although there
is widespread use of telepsychology to provide clinical
services within and outside of the VA [38], there is insuf-
ficient research to determine if telepsychology service
delivery is as acceptable or effective as traditional service
delivery for older adults. In addition it remains unknown
whether it is cost-effective for elderly veterans with depres-
sion residing in rural areas, without access to specialty
geropsychiatric services. Thus, research that addresses the
efficacy of this mode of service delivery is urgently needed.
This paper describes the rationale, study aims and objec-
tives, and research design and methods of an ongoing
four-year prospective, randomized clinical trial compar-
ing the effectiveness of Behavioral Activation treatment
for geriatric major depression delivered via in-home vide-
oconferencing technology ("Telepsychology") compared
to traditional face-to-face delivery ("Same-Room"), to test
the hypothesis that in-home "Telepsychology" service
delivery will be equally effective as the traditional mode
(Same-Room).
Rationale
The population of older adults is particularly well-suited
for telepsychology for several reasons: (1) Over the next
two decades there will be a large increase in the rural eld-
erly population, and access to care is already a significant
problem for many elderly adults with major depressive
disorder (MDD) [3]; (2) telepsychology may be preferred
by older adults, who avoid traditional mental health care
due to embarrassment or stigma [39-43]; and (3) telepsy-
chology may address significant age-related problems in
ambulation and transportation [3,44]. Indeed, medically
disabled older adults with ambulation difficulties, and
those isolated older adults in rural areas, are among those
at greatest risk of psychopathology, yet currently are the
least likely to be able to obtain treatment [3]. Finally,
results from a recent randomized trial also found telepsy-
chiatry to be efficacious in the treatment of mild cognitive
deficits among elderly persons [34].
Study Aims & Objectives
The objective of the study is to test the hypothesis that in-
home video-conferencing technology ("Telepsychology")
will be as effective as the more traditional mode of service
delivery ("Same-Room") for treating older adult veterans
suffering from major depressive disorder (MDD). This
objective will be accomplished by (1) Using an estab-
lished, highly effective and well-tolerated behavioral treat-
ment for depression (i.e. Behavioral Activation Treatment
for Depression (BATD) [45-47]; (2) Employing a rand-
omized between groups experimental design; (3) Examin-
ing standardized, repeated dependent measures of: (a)
clinical outcomes, such as symptom severity, social func-
tioning, and medical status; (b) process variables, such as
patient satisfaction, treatment adherence, and treatment
dropout rates; and (c) economic outcomes; and (4) con-
ducting analyses to examine for outcome differences
between African-American and Caucasian patients.
The primary research questions of the proposed study are:
1. Is in-home telepsychology for major depressive disor-
der in older adults as effective as same-room treatment on
clinical and process outcomes?
2. Is in-home telepsychology for major depressive disor-
der in older adults cost-effective?Trials 2009, 10:22 http://www.trialsjournal.com/content/10/1/22
Page 3 of 14
(page number not for citation purposes)
Methods
The study is a 2 group randomized controlled trial with
randomization of individual participants, blinded out-
comes assessments at baseline, mid-treatment (4-weeks),
post-treatment (8-weeks), 3-months, and 12-months, and
concurrent economic evaluation.
Location and Setting
The assessments and interventions will be conducted at
the primary care and mental health clinics of the Ralph H.
Johnson Veterans Affairs Medical Center (VAMC) located
in downtown Charleston, South Carolina. The Ralph H.
Johnson VAMC is a primary, secondary, and tertiary refer-
ral medical center providing acute medical, surgical, and
psychiatry inpatient care as well as primary care and spe-
cialized outpatient services. Currently, there are 98 acute
care beds and 28 nursing home care unit beds for a total
of 126 operational beds. The primary service area extends
from north of Myrtle Beach, SC, down to the surrounding
counties of Savannah (Georgia, USA). For the most recent
fiscal year (FY 2007), there were 41,645 unique patients,
4,000 discharges, 475,714 total outpatient visits, and
2,968 OEF/OIF enrollees and users. The Ralph H. Johnson
VA Medical Center is a part of VA Southeast Network VISN
7 which includes facilities in Charleston, SC, Columbia,
SC, Atlanta, GA, Augusta, GA, Dublin, GA, Birmingham,
AL, Tuscaloosa, AL, and Central Alabama (Montgomery
and Tuskegee campuses). The facility also has four Com-
munity Based Outpatient Clinics (CBOCs) in (1) Beau-
fort, SC – 53 miles to VAMC; (2) Goose Creek, SC – 17
miles to VAMC; (3) Myrtle Beach, SC – 83 miles to VAMC;
and (4) Savannah, GA – 84 miles to VAMC.
Ethics and Trial Registration
The study is funded by grant #IIR 04-421 from the Veter-
ans Health Administration Health Services Research and
Development program. The trial is approved by the joint
Institutional Review Board (IRB) of the Ralph H. Johnson
VAMC and the Medical University of South Carolina
(HR#16402). The trial is registered on the United States
National Institutes of Health Clinical Trials Registry (Clin-
icalTrials.gov identifier# NCT00324701), available online
at: http://clinicaltrials.gov/ct2/show/NCT00324701
Trial Population and Recruitment
Subjects will be 224 older male and female veterans (age
60 or older) presenting for services at VA primary care
clinics and meeting DSM-IV [48] criteria for MDD.
Actively psychotic or demented persons, individuals with
both suicidal ideation and clear intent, and individuals
meeting criteria for substance dependence will be
excluded from participation; however, in order to maxi-
mize generalization of results, presence of other forms of
psychopathology (eg, anxiety disorders) will not be a
basis for exclusion. Participants who are incapable of giv-
ing informed consent due to mental incapacity or extreme
distress will be excluded from the study. Because the
inclusion of minorities in research on psychiatric disor-
ders is important, about 40% of our sample will be Afri-
can American, which is representative of the population
of South Carolina.
We will use two complementary approaches to identify
eligible study subjects. The first method will consist of sys-
tematic identification of patients with MDD. After obtain-
ing IRB approval for a partial waiver of HIPAA, we will use
clinic-billing records over the previous 12-month period
to identify subjects with ICD-9 codes consistent with a
diagnosis of MDD. The physicians of eligible patients will
be notified of their patients' potential eligibility and asked
permission to enroll their patients in this study. After con-
sent is obtained from the physicians, letters of invitation
on clinic letterhead signed by the patient's physician will
be mailed to patients from the study clinics. The letter will
provide information about the study, explain the study
requirements, and clarify that only subjects that meet cer-
tain criteria will be eligible to participate in the study. The
letter will include an addressed and stamped post-card
that subjects can mail back to indicate interest or lack of
interest in participating in the study. In addition, the letter
will provide a telephone number that interested subjects
can call to receive detailed information about the study. In
the letter, subjects will also be informed that they will
receive a follow-up call in two weeks unless they mail back
the post card or call to decline being contacted. Subjects
that mail back the post card and express interest or call the
provided telephone number will receive detailed informa-
tion about the study. Subjects who agree to participate
will be asked to provide written consent and will be sched-
uled for the initial screening assessment.
The second method will consist of referrals from physi-
cians, other clinic staff such as nurses, or patients them-
selves in response to recruitment flyers for the study. The
Principal Investigator (PI) will share the goals of the study
and inclusion/exclusion criteria with physicians and clinic
staff during clinic administrative meetings. Physicians and
clinic staff will be asked to refer appropriate subjects to the
study research assistants. In addition, IRB approved
recruitment flyers will be posted in prominent locations
in the study clinics.
Regardless of recruitment pathway, research staff will
obtain written informed consent, complete a screening for
dementia and psychosis, and assure that participants meet
DSM-IV [48] criteria for MDD. Those candidates meeting
MDD criteria will then complete the remainder of the
assessment battery (Tables 1 and 2).Trials 2009, 10:22 http://www.trialsjournal.com/content/10/1/22
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Table 1: Data Collection Schedule
Study Instrument Screening
Visit
Baseline
Visit
4 Weeks Visit 8 Weeks Visit 3 Months Visit 12 Months Visit
Screening/Baseline Assessment
Demographic Questionnaire X
Geriatric Depression Scale X X X X X X
SCID X X
Short Portable Mental Status Questionnaire X
Multi-Method Assessment
Beck's Depression Inventory X X X X X
Beck's Anxiety Inventory X X X X X
SF-36 X X X X X
Medical Outcomes Study Social Support Form X X X
Morisky Medication Adherence Form X X X
Process Variables
Charleston Psychiatric Satisfaction Scale X X X X
Treatment Credibility X X X X
Service Delivery Perceptions X X X X
Treatment Adherence (Therapists) X X X X
Session Attendance/Attrition (Therapists) X X X X
Prior Computer/Audiovisual Tech. Experience X X X X
Resource Utilization
Baseline Visit Form X
Standard Follow-up Form XXTrials 2009, 10:22 http://www.trialsjournal.com/content/10/1/22
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Table 2: Study Instruments
Geriatric Depression Scale
(GDS) [51]
The GDS is one of the most widely used measures of depression in the 
elderly population using the generally accepted cutoff score of 11. This 
30-item measure shows good test-retest reliability and internal 
consistency. The GDS exhibits good concurrent validity, and excellent 
sensitivity, specificity, and positive predictive power in assessing 
depression with older adults.
The Short Portable Mental Status Questionnaire [85] This is a ten item test that is quickly completed and will be used to 
screen for cognitive impairment (cutoff ≥ 7). The screen is effective in 
identifying cognitive impairment in a variety of geriatric populations.
Structured Clinical Interview for DSM-IV
(SCID-IV) [50]
MDD and other psychopathology will be evaluated using this structured 
clinical interview based on the DSM-IV. The onset of the MDD will be 
specified. The SCID-IV has excellent interrater reliability on assessments 
of symptoms across a variety of disorders (overall kappa = 0.85).
Beck Depression Inventory
(BDI) [52]
The BDI is a 21-item self-report scale, is among the most widely used 
instruments to measure depression. The BDI has high internal 
consistency (α = 0.86 – 0.91).
Beck Anxiety Inventory
(BAI) [66]
The BAI is a 21-item self rating scale of anxiety symptomatology. Specific 
symptom clusters have been identified reflecting neurophysiological, 
subjective, panic, and autonomic dimensions. The BAI has good internal 
consistency and concurrent validity with the Hamilton Anxiety Rating 
Scale.
Medical Outcome Study Short Form-36 Health Survey (SF-36) 
[67]
The SF-36 is a 36-item questionnaire that measures health status and 
functioning over the past four weeks. The items vary from dichotomous 
(yes/no) responses, to ratings on a 6-point Likert scale. Responses are 
compiled into eight dimensions covering (a) Functional Status; (b) Well-
Being; and (c) Overall Evaluation of Health. The SF-36 has good test-
retest reliability as well as sensitivity to change in health status.
Medical Outcomes Study (MOS) Social Support Survey [86] It measures four functional components of social support: 1) tangible 
support; 2) affection; 3) positive social interaction; and 4) emotional or 
informational support. The total scale (α = 0.97) and subscales (α = 0.91 
to 0.96) have high internal consistency, good criterion and discriminant 
validity, and one-year test-retest reliability (0.72 to 0.76).
The Morisky Adherence Score [87] This is a commonly used self-report tool to assess adherence to 
medications. It has good validity and reliability. This scale asks patients to 
respond "yes" or "no" to a set of 4 questions. A positive response to any 
question indicates a problem with adherence with a total possible score 
of 4; higher scores indicate poorer adherence.
Charleston Psychiatric Outpatient Satisfaction Scale (CPOSS) 
[53]
The CPOSS is 16-item measure, with a Likert scale response format, 
based on a general measure of patient satisfaction. In a sample of 
patients preliminary data showed the measure had excellent reliability 
(alpha = 0.96) and good convergent validity with relevant anchor items 
("would you recommend this treatment to a friend or family member?").
Treatment Credibility Questionnaire [88] To assess for differences in outcome expectancy, treatment credibility 
scales developed by Borkovec and Nau (1972) will be used. Four of the 
questions will be used for this study, with 10-point Likert scales. These 
include questions regarding how logical the treatment seems, how 
confident participants are about treatment, and their expectancy of 
success.
Service Delivery Perceptions Questionnaire This questionnaire will be used to assess subjects' perceptions about 
variables specifically related to the mode of service delivery (e.g., the 
quality of communication, ease of use, willingness to use treatment).
Prior Experience with Computer and Audiovisual Technology 
Questionnaire
We will administer a short measure to learn more about participants' 
prior experiences and comfort level with computers and audiovisual 
technology.Trials 2009, 10:22 http://www.trialsjournal.com/content/10/1/22
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Randomization
The study coordinator will verify all eligibility criteria
prior to randomization. The procedure and risks will be
explained to the patient and the consent form signed as
per standard clinical practice. All subjects will be ran-
domly assigned to one of two groups – Telepsychology (n
= 112) and Same Room (n = 112). The randomization
sequence will be generated by the senior biostatistician
and provided in individual sealed envelopes to the data/
statistical analyst who will be responsible for randomiza-
tion. This information will remain confidential and not
shared with the study sites in accordance with the CON-
SORT guidelines [49]. The study coordinator will call the
data/statistical analyst to get subject randomization
assignment. Once a randomization assignment is pro-
vided, the patient is entered into the study and will be
included in the intention to treat analysis (Figure 1).
Intervention and Control Groups
All subjects will receive the same individual mental health
intervention for an 8-week period. Sessions will occur
approximately once each week during this period, and
each session will last for about 60 minutes. The interven-
tion group (Telepsychology) will receive therapy via
videophone while the control group (Same Room) will
receive face-to-face therapy. All patients will receive 8 ses-
sions of BATD. One of the strengths of the BATD protocol
is that it is designed to be very straightforward, easily
learned by therapists and patients, and can be imple-
mented over an 8-session period. Initial sessions are used
to build patient rapport and provide a rationale for activa-
tion-based treatment. Subsequent sessions are used to
assess factors that might be maintaining depressed behav-
ior (eg, determining if a deficit of reinforcing activities or
a preponderance of punishing activities exists); assess
functional aspects of the behavior itself (eg, is the
depressed person receiving significant social reinforce-
ment for being depressed); initiate efforts to increase the
likelihood of engaging in reinforcing behaviors; and
reduce the availability of unintended reinforcement for
depressed behavior. Next, a systematic approach to behav-
ioral activation is implemented. This is simply a process to
increase the rate of enjoyable (ie, going to dinner with a
friend) and functional (ie, grocery shopping) behaviors,
with this increase resulting in a decrease in depression.
Using a daily calendar, patients begin with a weekly self-
monitoring exercise that serves as a baseline assessment of
daily activities, and orients them to the quality and quan-
tity of his or her activities on a daily basis. Following the
introductory and assessment stages of BATD, emphasis in
sessions two and three shifts towards the identification of
goals within key life areas including relationships,
employment, recreational activities, physical/health
issues, and spirituality. From these goals, the individual
will select specific behaviors that will help achieve these
objectives. For example, the life area of family relation-
ships may include the goal of rebuilding a relationship
with a particular family member, which can be accom-
plished with specific behaviors such as calling the family
member twice per week. To help facilitate engagement in
the desired behaviors, each activity is placed within an
activity hierarchy and rank-ordered from "easiest" to
"most difficult" to accomplish. Patients then use a daily
calendar to plan, in advance, the next week wherein they
schedule a variety of activities, including both 'fun' (such
as something they enjoy doing) or 'functional' (such as
getting some undesirable chore out of the way so they do
not have to worry about it any longer). The planning cal-
endar serves as an activity log (in instances where patients
do not follow the planned activity, they are instructed to
update the calendar to reflect what they actually did).
Behavioral Checkouts, or specific reviews of completed
activities and concurrent moods are completed with ther-
apists in session to monitor progress over the course of
treatment as the patient graduates to different levels of the
hierarchy of activities.
The therapist and patient collaboratively ensure that the
behaviors that they are planning fit well within the life
area and goals in that area as previously established. At the
beginning of each session, the behavioral checkout occurs
in which adherence to the planned calendar of activities is
reviewed, and ensuing mood states are discussed. Specific
behaviors and contextual parameters, including time of
occurrence and duration of activity, are determined on the
basis of the patient's level of success or difficulty with
activities for the prior week. As an additional incentive for
patients to complete the behaviors on the behavioral
checkouts, patients are asked to identify and schedule
weekly rewards, arranged to become available only after
they have completed the planned activities a particular
week. The treatment is flexible and we ensure that all
activities (eg, pleasant activities lists) are age, gender, and
culture appropriate.
Resource Utilization Questionnaire [89] Previously validated questions on resource utilization will be 
administered as part of the baseline, 3-, and 12 month assessments. The 
questionnaires are 1 page long and capture information on 
hospitalizations, physician/professional visits, and medications. The 
baseline assessment will capture differences between groups and allow 
for the control of possible group variation during data analysis.
Table 2: Study Instruments (Continued)Trials 2009, 10:22 http://www.trialsjournal.com/content/10/1/22
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Design and Study Flow Figure 1
Design and Study Flow.
 
 
Screening and eligibility   
assessment 
Baseline assessment 
Randomization 
Same Room Group

Telepsychology Group  
N=112  
 
N=112  
Mid-treatment assessment 
(Week 4) 
Post-treatment assessment 
(Week 8) 
3 month follow-up 
12 month follow-up Trials 2009, 10:22 http://www.trialsjournal.com/content/10/1/22
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Upon completion of the active treatment program
described above, subjects from both conditions (Telepsy-
chology, Same-Room) will be followed for 12 months.
The outcome assessment battery will be administered to
all subjects at the end of this follow-up period. Those who
develop acute problems during follow-up will either be
provided additional treatment by the project staff or will
be referred to other appropriate treatment providers. In
order to prevent distortions in the follow-up data, infor-
mation on patients who receive further treatment will be
analyzed separately.
Telecommunications Technology
Treatment sessions for the Telepsychology condition will
be conducted using in-home videoconferencing technol-
ogy. We will use an analogue videophone (KMEA
TV500SP, Figure 2) that operates via plain old telephone
service (POTS). Apart from the video screen, this equip-
ment appears and functions much like a basic touch-tone
telephone. It is a "plug-and-use" product, with built-in
camera, full duplex speakerphone, 4-inch LCD color
screen (270 K pixels) with real-time motion display (18
frames per second), and oversized touch-tone buttons for
easy use by all patients. This equipment is simple to use.
If necessary, project or clinic staff will be available to visit
participants in their homes to help set up the equipment.
We will track the type and amount of assistance required
across sessions in order to help anticipate future difficul-
ties with in-home use.
Study Instruments and Data Collection Schedule
Self-report measures will be used to evaluate clinical out-
come at baseline, mid-treatment (4-weeks), post-treat-
ment (8-weeks), 3-months, and 12-month follow-up.
Process outcomes will be evaluated at 4-weeks, 8-weeks,
3-months, and 12-months. Resource Utilization surveys
will be administered at baseline, and then 3 and 12
month follow-up. Endpoint psychiatric interviews (ie,
Structured Clinical Interview for DSM-IV, [SCID]) [50];
will be administered at baseline and 12-months by raters
blind to subject condition. Structured interviews will be
audiotaped, and 20% will be rated by an independent to
ensure interrater reliability. The complete assessment
takes about 120 minutes. Study assessments will be
administered by either the Research Coordinator. Assess-
ment clinicians will not deliver treatment. Their training
will include instruction, assigned readings, modeling,
role-playing, and feedback.
Therapist Training and Supervision
The same counselors will conduct the individual BATD
treatment for both conditions (Telepsychology, Same-
Room). At the start of the project, treatment providers will
undergo a 12-hour training program with the clinical psy-
chologist/project consultant and the developer of the
BATD treatment manual. During the project, therapists
will follow the BATD treatment manual, and will undergo
weekly peer supervision with an experienced clinical psy-
chologist on the team. Thus, a highly experienced and
expert team of mental health care providers will imple-
ment the treatment for the subjects in this study. We have
used a similar training approach in our other studies.
Treatment Integrity and Adherence
A quantitative measure of protocol adherence will be
obtained using a checklist of the specific procedures
scheduled to be followed in the BATD treatment manual.
To ensure treatment adherence, all sessions will be audio-
taped, and 20% of these will be rated for competence and
adherence by co-investigators. To evaluate adherence to
treatment protocol, rating forms that use a 7-point Likert
scale were developed and assess how well the therapists
accomplished relevant behavioral tasks for each session.
Two raters, blind to treatment condition, will rate tapes
independently to allow for computation of inter-rater reli-
ability. Our rating forms are modeled after the therapist
rating forms used in other studies of cognitive-behavioral
treatments, including our own treatment outcome studies
that successfully demonstrated therapist fidelity to a man-
ualized cognitive behavioral intervention delivered via
"telepsychology" [27]. This will allow us to study any dif-
ferences between conditions on non-specific factors, such
as therapist empathy and rapport. Videophone Figure 2
Videophone.Trials 2009, 10:22 http://www.trialsjournal.com/content/10/1/22
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Outcome Measures
Clinical Outcome Measures
The primary clinical outcome measure is the proportion
(%) of patients who respond to treatment. Treatment
Responder status will be determined using each of the
dependent measures of depression (ie, Geriatric Depres-
sion Scale (GDS) [51]; Beck Depression Inventory (BDI)
[52]; and SCID [50]. For the BDI and GDS, treatment
responders will be those that demonstrate, at 12-month
follow-up, improvement of at least 50% on the total
score. For the SCID, treatment responders will be those
who are no longer diagnosed with MDD. Dichotomous
classifications for the GDS and the BDI will be achieved
by defining treatment response as at least a 50% improve-
ment from baseline to post-treatment level (percent
change from baseline: [baseline-post]/baseline ≥ 50%).
We will report analyses involving each measure of treat-
ment response separately, but will take the a priori posi-
tion that, in the case where results based on each of these
analyses do not converge, overall conclusions regarding
treatment response will be based on the two measures
that concur. Thus, our indicator of treatment response will
be in terms of each measure, as well as in terms of the con-
verging data from at least two different measures.
The primary process outcome is score on the Charleston
Psychiatric Outpatient Satisfaction Scale (CPOSS), [53]
measured at the end of the 12-month follow-up period.
The CPOSS is a 16-item measure with each item having a
Likert-type format (total score is sum of the 16 items with
range 16–80). Non-inferiority of patient satisfaction at the
end of the 12-month follow-up period for the two modes
of delivery will be evaluated via the one-sided non-inferi-
ority 90% confidence interval approach to estimate the
difference in end of study mean scores on the CPOSS for
the Telepsychology and Same-Room conditions. The
magnitude of the difference in satisfaction levels, as esti-
mated by the confidence interval will provide useful clin-
ical information and will allow a clinical judgment
relative to the clinical non-inferiority of the of the two
modes of delivery.
Economic Outcome Measures
The economic analysis will determine the cost and poten-
tial cost savings of Telepsychology. Comprehensive infor-
mation will be gathered on 1) telepsychology-related
capital expenditures, and 2) patient-related resource utili-
zation over 12 months for all patients in the project. This
will allow us to estimate the combined spectrum of invest-
ment expenditures and direct in-hospital cost of Telepsy-
chology as well as cumulative health costs over 12
months. In addition, a Markov-type economic model
[54], determining transition probabilities between differ-
ent health states, will be developed to predict flow of
funds and event rates over a 12-month period for Telepsy-
chology participants based on outcomes.
Sample Size Determination and Power Analysis
The primary response variable for sample size calculation
is the proportion (%) of patients who respond to treat-
ment. Treatment response is defined as at least a 50%
improvement from baseline to post-treatment level on the
GDS [percent change from baseline: (baseline-post)/base-
line  ≥ 50%]. Demonstration of non-inferiority among
treatments differs from that of establishing superiority.
For a non-inferiority trial, the null hypothesis states that
two treatments are non-equivalent, that is they differ by at
least a clinically relevant amount, Δ. [55-62]. The
approach will be formulated in terms of the one-sided
non-inferiority problem [55,60,61,63] because it is of
interest only to test that the treatment response (%
responders) for the Telepsychology mode of delivery is
not too low compared to that for the standard Same-
Room mode of delivery. Note that, for non-inferiority tri-
als, the consequence of a false positive (ie, claiming the
novel therapy [Telepsychology] is worse than the standard
therapy [Same-Room] when it is, in fact, non-inferior) is
to keep patients on the standard therapy. Therefore, the
Type I error rate, α, can be set higher than in traditional
superiority trials (eg 0.1–0.2) [64].
We estimate that the % treatment responder for Same-
Room delivery (P) is 0.70. We assume that a maximum
clinically unimportant difference in response proportion
(Δ, the non-inferiority effect size) is 0.15 between Telepsy-
chology and the standard Same-Room service delivery
(upper limit of one-sided 90% confidence interval must
not be greater than Δ = 0.15 for the conditions to be
declared equivalent). Using the tables of Machin and
Campbell [64] and assuming Δ = 0.15, one-sided α = 0.10,
P = 0.70, and power = 0.85, we estimate that approxi-
mately n1 = n2 = 100 subjects per condition are needed for
overall treatment effects comparisons. If we further
assume that 10% of subjects will not have at least one post
baseline measurement (i.e. will not be included in the ITT
sample), then 112 subjects must be randomized to each
treatment group to yield the required sample size for the
primary intent-to-treat analyses (n1 = n2 = 100/group).
For the ITT sample (n1 = n2 = 100/treatment group) we
will be able to estimate the individual (main effects) end
of treatment means for each of the continuous clinical
and process measures with a precision of ± 0.2 standard
deviations. For the primary outcome measure ΔΔ1  =
Δ(Post)T- Δ(Post)S, which measures the difference in change
from baseline (pre to immediate post treatment) for the
continuous outcome domain measures for the telepsy-
chology condition compared to change from baseline for
the standard (same-room) condition, we will be able toTrials 2009, 10:22 http://www.trialsjournal.com/content/10/1/22
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estimate with a precision of ± 0.3 standard deviation units
using 95% confidence intervals for the difference in two
means (Δ(Post)T, Δ(Post)S), where the appropriate standard
deviation is the pooled standard deviation for comparing
change from baseline for the telepsychology condition
versus the standard condition.
Assuming that 20% of subjects will drop out of the ITT
sample (n1 = n2 = 80, assuming equal treatment distribu-
tion of dropouts), we will be able to estimate for the com-
pleter sample the individual end of treatment means for
each of the measures with a precision of ± 0.2 standard
deviations, and the difference in change from baseline
(pre to immediate post treatment) for the outcome
domain measures with a precision of ± 0.3 standard devi-
ation units.
Both the standard deviation and the distribution of costs
are presently unknown for the type of patients who will be
enrolled in Telepsychology. Thus, it is difficult to obtain a
meaningful estimate of the power to detect a difference in
CE from any arbitrary value. We propose to determine
costs and apply to our economic model after the comple-
tion of the study, and then use the bootstrap technique to
obtain a 90% Confidence Interval (CI) around the esti-
mated costs. The bootstrap technique is appropriate
because, as noted, the distribution of costs for these types
of patients is presently unknown.
Data Analysis
Primary Clinical Outcome
Testing the non-inferiority of the Telepsychology mode of
delivery to the standard Same-Room mode in terms of %
responders can be carried out through either a confidence
interval approach or through a modified hypothesis test-
ing procedure [55-62]. For both approaches, a conclusion
that the two modes of delivery are similar in clinical effi-
cacy (non-inferior) requires that the response proportion
(% responders) for the standard delivery (Same-Room)
cannot exceed by more than Δ the response proportion for
the novel delivery (Telepsychology). We assume Δ = 0.15
between the novel delivery and the standard delivery
(one-sided non-inferiority). With the confidence interval
approach, the upper limit of the one-sided 90% confi-
dence limit for the difference in % responders for the
novel delivery (Telepsychology) and the standard delivery
(Same-Room) must be 0.15 (Δ) or less to accept the
hypothesis of a non-inferior novel treatment. Statistically,
this translates into testing a non-zero difference between
the treatments, where noninferiority is established by
demonstrating that the difference between treatments is
less than the maximum clinically unimportant difference
in response proportions, Δ[55-57,59,61,62]. The hypoth-
esis testing approach to evaluating equivalency in %
responders, with an appropriately adjusted test statistic as
described by Dunnett and Gent [56] and Farrington and
Manning [57] will also be used.
In addition to comparing unadjusted % responders
between the modes of delivery conditions, it also is of
interest to compare % responders, adjusted for putative
confounding variables. Possible covariables to be consid-
ered for inclusion in these analyses include initial disease
severity as measured by baseline GDS or BDI score, use of
psychiatric medication, number of other co-morbid con-
ditions, and relevant others as identified though the pre-
liminary descriptive analyses. Two approaches will be
used to evaluate non-inferiority of adjusted % responders
for the two delivery conditions. The method of Gart and
Nam [65] and Nam [59], which involves calculation of a
non-inferiority test statistic within strata of potential con-
founding variables, formulates a score test for a null
hypothesis of a common specified clinically relevant non-
zero difference in % responders between two treatments
for multiple 2 × 2 tables. Because the above procedure
may be limited by the number of covariables (number of
strata) that can be used, we will carry out a second set of
analyses using a multivariable logistic regression model to
obtain estimates of adjusted % responding for each treat-
ment delivery condition for a specified set of values for the
covariables, and then will apply the methods described
above (one-sided confidence intervals and non-inferiority
hypothesis testing) to evaluate non-inferiority of the two
interventions. The response variable for these analyses is
the dichotomous outcome, responder/non-responder to
treatment, with missing data from premature exits treated
as non-responders. The primary independent variable is
treatment condition.
Secondary Analyses
The one-sided non-inferiority 90% confidence interval
approach (as described above) to evaluate noninferiority
using the difference in change from baseline mean scores
for the continuous clinical measures; GDS [51], BDI [52],
BAI [66], SF-36 [67]; for the Telepsychology and Same-
Room conditions will be used. The magnitude of the dif-
ference in the means (effect sizes), as estimated by the
confidence intervals will provide useful clinical informa-
tion and will allow a clinical judgment relative to the clin-
ical non-inferiority of the two modes of delivery. The
hypothesis testing approach to evaluating noninferiority,
as described by Dunnett and Gent [56] and Farrington
and Manning [57], will also be used.
Additional Analyses
In additional analyses, using the intent-to-treat sample
and the baseline (week 0), mid- (week 4) and post- (week
8) active-treatment (randomized) phase values for contin-
uous clinical variables (GDS, BAI, BDI, SF-36, patient rat-
ings, functional status indicators), we will use randomTrials 2009, 10:22 http://www.trialsjournal.com/content/10/1/22
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regression models (RRM) analyses (or equivalently, hier-
archical linear model [HLM] or mixed effects models) to
compare the Telepsychology and Same-Room conditions
over the 8-week active phase time tracjectory. These anal-
yses will use scores for each outcome as the dependent
variable and delivery mode (treatment) and time (time by
treatment) as the primary independent variables. The ran-
dom regression approach estimates individual change in
outcome for each subject in addition to estimating aver-
age change in outcome within each treatment population.
Specifically, random regression models allow for meas-
urement of subjects at different time points, missing data,
and time varying or invariant covariates [68-74]. Further,
longitudinal methods for binary outcomes [75-77] will be
used to compare the Telepsychology and Same-Room
conditions for the dichotomous outcome measure (MDD
response status measured at weeks 4 and 8). Methods for
categorical or ordinal outcomes [78-82] will also be
applied where appropriate.
Exploratory multivariable logistic regression, assuming
drop-outs are nonresponders, will be used to determine
the set of predictor variables associated with treatment
response (dichotomous outcome: treatment responder/
nonresponder as described under primary analyses). In
additional exploratory analyses, RRM analysis will be
used to evaluate the effect of putative confounding or
prognostic variables on continuous or binary clinical out-
comes following the 8-week treatment course, and the
possible effect modification (interaction) of these varia-
bles on the relationship between treatment status (deliv-
ery mode) and clinical outcome. Interaction between
treatment status variables and covariates will be evaluated
by inclusion of treatment by covariate interaction terms in
the model. In a final set of analyses, we will compare the
single end of study measure (change from baseline) for
the outcome variable using a multivariable regression
approach with treatment status as the primary independ-
ent variable, with missing values imputed using the
method of Little and Rubin [83]. Analyses will be repeated
for each of the clinical measures, both with and without a
Bonferroni correction [84] for the multiple outcome vari-
ables. In other words, both the unadjusted and Bonfer-
roni-corrected p-values will be obtained to evaluate
sensitivity of conclusions to the "multiple comparisons"
effect.
Economic Analyses
A Markov-type economic model will be used to predict
flow of funds and event rates over a 3-month and 12-
month period for populations with depression based on
outcomes and effectiveness data. The model will use
actual event data reported by participants through survey
at follow-up. The reason for including all costs is that it is
sometimes difficult to distinguish depression-related
from non-depression events. However, we will attempt to
separate hospitalizations and office visits associated with
a patient's depression problems from non-depression epi-
sodes of care. Another reason for including all costs is that
depression is comorbid with many other conditions and
the benefit of treatment may go beyond mental health
costs. Thus, we will measure total cost savings and, based
on patient response, separate depression-related costs
from the cost offset. Capital costs will be annualized and
depreciated over the life of the equipment, thus calcula-
tions for a 12-month period should be straightforward.
Potential costs savings of Telepsychology will be based on
sensitivity analysis of the fluctuations in the proportion of
those appropriately treated with traditional Same-Room
mental health care service delivery, compared to the
actual proportion from those in the Telepsychology anal-
ysis.
Patient-oriented resource utilization data will be linked to
participant's clinical data and a set of standard cost
weights developed from archival VA billing data sources
from patients with depression. The resources reported by
the study participants (including medications) will be
converted to dollar values using standard cost weights
estimated from DSS administrative data. Average cost per
day and average cost per admission will be calculated.
Outpatient costs will include the average cost per clinic
visit. Cost weights will be applied to the survey responses.
To gain further insight into the variation in the resource
utilization and costs of Telepsychology, sensitivity analy-
ses will be performed. Sensitivity analysis involves system-
atically altering our assumptions about the costs and
health effects of Telepsychology and noting the effect on
the resulting cost/savings estimates. Two types of sensitiv-
ity analyses will be performed. The first set of calculations
will be one-way sensitivity analyses. In one-way sensitivity
analysis, the assumption about each parameter (eg, cost of
telepsychology hardware) is varied over a reasonable
range of values with all other parameters fixed. Finally, we
will develop favorable and unfavorable scenarios for Tel-
epsychology based on various assumptions including, but
not limited to capital costs of telepsychology, technology
"downtimes," and clinical outcomes. Because the specifics
of these scenarios will depend on the nature of our find-
ings, we cannot describe fully these analyses a priori.
Nonetheless, these scenarios will reflect our understand-
ing of the variation surrounding the cost estimates and the
correlations among those parameters.
Cost data will be displayed in tables to highlight the
extent to which costs cluster around videoconferencing
technology, as well as patient-related utilization such as
initial hospitalizations, outpatient visits, non-healthcare
patient costs, medications and readmission(s). Costs will
also be displayed graphically in a cumulative fashion,Trials 2009, 10:22 http://www.trialsjournal.com/content/10/1/22
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with cost on the horizontal axis and percent of patients
with a specified or lower cost on the vertical axis. Finally
costs will be displayed over time, with time on the x axis
and mean cost on the y axis. Means and standard devia-
tions of costs will be presented for each component of
cost. "Trimmed" means and standard deviations of costs
will be presented when 10% largest values and 10%
smallest values are ignored. This way the summary statis-
tics are less influenced by a small number of extreme out-
liers. Another possibility is to consider median as a
measure of location and inter-quartile range as a measure
of variance. However the usual or trimmed means and
standard deviations seem more appropriate for this anal-
ysis because health care providers and payers may be con-
cerned more about average cost, not median cost.
Discussion
Study recruitment commenced in April 2007, with all fol-
low-up assessments associated with the study expected to
be completed by June 2010. As of October 2008, 171 par-
ticipants have been screened and 111 have been rand-
omized. Of the number randomized, 80 have completed
Week 4 assessments, 72 have completed Week 8 assess-
ments, 39 have completed Month 3 assessments, and 6
are due to complete Month 12 assessments.
Addressing a significant knowledge gap, this study is a
prospective, randomized evaluation of clinical, process,
and cost outcomes for a mental health intervention. The
study will test the hypothesis that in-home Telepsychol-
ogy service delivery will be equally effective as a tradi-
tional mode (Same-Room). If this study demonstrates
telepsychology efficacy is equivalent to Same-Room serv-
ice delivery, future research and program development
will focus on bringing a wide range of specialized mental
health services to the homes of veterans and community
based outpatient clinics (eg, CBOCs, Veteran Centers) via
videoconferencing technology. If Telepsychology non-
inferiority and cost-effectiveness can be empirically estab-
lished, research that examines a range of important system
issues, including effectiveness outcomes and service deliv-
ery strategies to maximize the accessibility of mental
health services for rural veterans can proceed. We antici-
pate that future research projects would include examina-
tion of telepsychology applications for providing
individual and group mental health care to people with a
range of other mental illnesses. Furthermore, we will also
be able to evaluate the association between process and
outcome measures in this study, which will have implica-
tions for future telepsychiatry efforts, as well as more gen-
eral treatment outcome efforts with older veteran
populations. Thus, while meeting the VA's mission to pro-
vide quality health care to all veterans, this project repre-
sents an important step in a programmatic line of
research, including planned future VA HSR&D applica-
tions in mental health service delivery and care coordina-
tion to rural and underserved populations.
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